trending Market Intelligence /marketintelligence/en/news-insights/trending/fj8fyyoZDyo2L9l4l4uJVA2 content esgSubNav
In This List

Granules India to sell entire stake in joint venture to Ajinomoto Bio-Pharma

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Granules India to sell entire stake in joint venture to Ajinomoto Bio-Pharma

Granules India Ltd. agreed to divest its remaining 50% stake in a joint venture to its partner Ajinomoto Bio-Pharma Services.

The Indian JV company, Granules OmniChem Pvt. Ltd., was formed in 2011 to provide small molecule intermediates and active pharmaceutical ingredients manufacturing to the pharma sector. It will now be fully owned by Ajinomoto Bio-Pharma.

Financial details of the transaction were not disclosed.

The deall's closing, which is subject to closing conditions and regulatory approvals, is expected in the fourth quarter.

Hyderabad-based Granules India manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates and finished doses.

San Diego-based Ajinomoto Bio-Pharma focuses on small and large molecule manufacturing, drug product manufacturing and other preclinical trial supply services.